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The generation of NO by the various NO synthases in normal and malignant tissues is manifested by
various biological effects that are involved in the regulation of cell survival, differentiation and cell death.
The role of NO in the cytotoxic immune response was ﬁrst revealed by demonstrating the induction of
iNOS in target cells by immune cytokines (e.g. IFN-γ, IL-1, TNF-α, etc.) and resulting in the sensitization of
resistant tumor cells to death ligands-induced apoptosis. Endogenous/exogenous NO mediated its im-
mune sensitizing effect by inhibiting NF-κΒ activity and downstream, inactivating the repressor tran-
scription factor YY1, which inhibited both Fas and DR5 expressions. In addition, NO-mediated inhibition
of NF-κΒ activity and inhibition downstream of its anti-apoptotic gene targets sensitized the tumor cells
to apoptosis by chemotherapeutic drugs. We have identiﬁed in tumor cells a dysregulated pro-survival/
anti-apoptotic loop consisting of NF-κB/Snail/YY1/RKIP/PTEN and its modiﬁcation by NO was re-
sponsible, in large, for the reversal of chemo and immune resistance and sensitization to apoptotic
mechanisms by cytotoxic agents. Moreover, tumor cells treated with exogenous NO donors resulted in
the inhibition of NF-κΒ activity via S-nitrosylation of p50 and p65, inhibition of Snail (NF-κΒ target
gene), inhibition of transcription repression by S-nitrosylation of YY1 and subsequent inhibition of
epithelial–mesenchymal transition (EMT), induction of RKIP (inhibition of the transcription repressor
Snail), and induction of PTEN (inhibition of the repressors Snail and YY1). Further, each gene product
modiﬁed by NO in the loop was involved in chemo-immunosensitization. These above ﬁndings de-
monstrated that NO donors interference in the regulatory circuitry result in chemo-immunosensitization
and inhibition of EMT. Overall, these observations suggest the potential anti-tumor therapeutic effect of
NO donors in combination with subtoxic chemo-immuno drugs. This combination acts on multiple facets
including reversal of chemo-immune resistance, and inhibition of both EMT and metastasis.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Since the early introduction of various nonspeciﬁc che-
motherapeutic drugs and, subsequently, radiotherapeutics, hor-
monal drugs and immunotherapies, there have been signiﬁcant
clinical and objective responses in patients with various malignant
diseases. While these therapeutic strategies continue to improve
and are still currently in use in oncology, there remains a major
problem in that a subset of cancer patients does not initially re-
spond and another responding subset develops resistance to fur-
ther treatments and both subsets succumb to the disease. Clearly,
the non-responding patients underlie the rapid and successful
development of new classes of targeted therapeutics based on the
various molecular mechanisms that govern resistance. Note-
worthy, it is recognized to date that many of the cytotoxic agents
(drugs, hormones, immunotherapies) used in cancer therapy
mediate their effects by inducing programmed cell death, or
apoptosis, in the responding sensitive tumor cells. Hence, a major,
but not the only mechanism of resistance, is the mechanism in
acquisition of tumor cells of several molecular and genetic means
to evade cell death by apoptosis.
The inhibition of pro-apoptotic pathways in cancer cells is the
result of tumor cells exhibiting constitutively hyperactivated sur-
vival and proliferative signal pathways that counteract the pro-
apoptotic pathways. A good example is the constitutively hyper-
activated NF-κB pathway in the majority of cancers that was
shown to play a pivotal role in tumorigenesis, angiogenesis, re-
sistance, inﬂammation, immunomodulation, and metastasis. Fur-
ther, other survival/proliferative/anti-apoptotic pathways are also
upregulated in cancer cells such as the PI3K/AKT and MAPK
pathways. These various pathways also crosstalk and synergize in
their anti-apoptotic effects [1,2].
There have been several strategies to therapeutically inhibit
anti-apoptotic pathways in cancer. Among these, many earlier and
recent studies suggested the potential cytotoxic and sensitizing
effects of NO in examined various cancer cell models, in vitro and
in vivo [3–10]. Recently, Reynolds el al. [11] reviewed the use of NO
in the inhibition of tumor cell proliferation and its consideration as
a novel therapeutic.2. Nitric oxide properties and applications
Nitric Oxide is a versatile and pleiotropic molecule. It has been
reported to be involved in cell signaling and it regulates a variety
of physiological functions in mammals [12,13]. NO is a lipophilic
free radical gas that can readily diffuse through cell membranes
and chemically reacts with metal containing proteins and other
effector molecules. NO is synthesized from arginine by the nitricoxide synthases (NOS). Three types of NOS have been discovered,
namely, eNOS (endothelial nitric oxide synthase or type III NOS),
nNOS (neuronal nitric oxide synthase or type I NOS), and iNOS
(inducible nitric oxide synthase or type II) [14]. Zinc ﬁnger proteins
have been reported to be important targets of NO [15] and NO can
also mediate nitrosation and nitrosylation of various proteins and
affects their functions and activities [16–19].
The guanylyl cyclase (sGC) α-1 and α-2 heterodimers are found
in many tissues and are the receptors for NO [20,21]. The gen-
eration of NO by nitroglycerine or nitroprusside activates soluble
guanylate cyclase (sGC) to produce cyclic guanosine monopho-
sphate (cGMP) that, in turn, activates Protein kinase C (PKC) to
phosphorylate proteins [22]. The recent ﬁndings by Bian and
Murad [23] established that the NO/sGC/cGMP axis is involved in
the regulation of proliferation and differentiation. They also re-
ported that undifferentiated tumor cells and stem cells have low
levels of sGC. Thus, by elevating endogenous cGMP it resulted in
the inverse correlation with the proliferation and colony formation
of glioma cells.
The various NOS isoforms' functions are interconnected and
operate as a pivotal part of Red-OX-based molecular signaling
systems that result in major impacts on the cell's physiology and
behavior and include S-nitrothiols (SNOs), which are generally
produced by S-nitrosation of cysteine thiols by NO. These result in
the disruption or dysregulation of normal cell signaling and in the
impairment of cellular functions [19,24]. Both eNOS and nNOS are
calcium-dependent, but iNOs is calcium independent. Further,
eNOS and nNOS release lower levels of NO whereas iNOS releases
high levels of NO [25]. Of relevance, NO signaling has been re-
ported to initiate apoptosis through its activity on the mitochon-
drial membrane permeability and the consequent release of cy-
tochrome c oxidase [6, 26].
NO-mediated apoptosis consists also in the endogenous for-
mation of reactive nitric oxide species (RNOS). These RNOS include
superoxide (O2 ) that reacts with NO to form peroxynitrite
(ONOO) that strongly induces apoptosis. Peroxynitrite acts as a
DNA oxidant and induces single strand breaks in DNA [27,28].
Also, NO induces changes in the mitochondrial permeability
transition pore (MPTP) and its opening results in the release of
cytochrome c into the cytoplasm and induces apoptosis via bind-
ing Apaf-1 that activates caspase-9 leading to the activation of
caspases 7 and 3 and downstream apoptosis [29]. The release of
cytochrome c also results in the signiﬁcant release of intracellular
calcium resulting in cell death [30].
The consideration of the potential therapeutic application of
NO donors has been the subject of many reports and reviews [7–
9,11,13,31–33]. In this review, we will brieﬂy discuss (1) the roles
of NO-mediated regulation/interference of gene products that
form a loop, namely, the NF-κB /Snail/YY1/RKIP/PTEN loop, that
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also involved in drug/immune resistance (2) the roles of NO-
mediated chemo- and immunosensitizations of resistant cancer
cells to apoptosis by chemo-immuno cytotoxic agents (3) the role
of NO donors in the inhibition in vivo in mice bearing tumor xe-
nografts when used in combination with chemotherapy and
(4) the clinical response in cancer patients treated with NO-
mediated therapeutics.3. NO-mediated interference in the dysregulated NF-κB/Snail/YY1/
RKIP/PTEN loop responsible for chemo- and immune-resistance in
cancer cells
Based on reported studies by us and others, we have estab-
lished the presence of a dysregulated NF-κB/Snail/YY1/RKIP/PTEN
loop in cancer cell model systems that regulates resistance and
metastasis [34–38]. Each gene product of the loop was pivotal in
the regulation of tumor cell sensitivity to various cytotoxic apop-
totic stimuli (e.g., chemotherapeutic drugs, cytotoxic cells, cyto-
toxic ligands including FasL, TRAIL, and TNF-α). Treatment of tu-
mor cells with high levels of NO donors (e.g., greater than 500 mM
DETA-NONOate) resulted in the inhibition of the upregulated gene
products in the loop, namely, NF-κB, Snail, and YY1 and the de-
repression of down regulated gene products, namely, RKIP and
PTEN. These NO-mediated effects were both direct and indirect
and resulting in tumor cells' inhibition of cell proliferation and
their sensitization to apoptotic stimuli.
Brieﬂy, we present below the ﬁndings of NO-mediated effects
on each of the gene products of the above loop.
3.1. NO-mediated inhibition of NF-κB
The transcription factor NF-κB is constitutively hyper-activated
in many cancers and regulates, in large part, survival, proliferation,
anti-apoptotic activity, angiogenesis, and metastatic properties of
cancer cells [39]. The role of NF-κB in resistance to apoptotic sti-
muli is the result of the activation downstream of anti-apoptotic
gene products such as XIAP, Bcl-xl, Bcl-2, and YY1 [40–43]. Hence,
inhibition of NF-κB may reverse the above tumorigenic properties
and reverse drug resistance. The inhibition of NF-κB by various
agents, including drugs, small molecule inhibitors, siRNA, etc.,
results in the reversal of tumor cell resistance to apoptotic stimuli
and sensitization to apoptosis by chemo-immunotherapeutic
drugs [44–48].
Nitric oxide, endogenous or exogenous, mediates contrasting
effects on tumor cells, namely, it can either promote or inhibit
tumor cell survival and growth. These contrasting effects were
found to be dependent on the level of NO; low level of NO is pro-
tumorigenic whereas high level is anti-tumorigenic [49]. High le-
vel of NO inhibits NF-κB activity by inhibition of both the phos-
phorylation and degradation of IκBα and, thus, preventing NF-κB
nuclear translocation and gene transcription [50]. NO will react
with reactive oxygen species such as superoxide resulting in an
impaired activation of NF-κB [51]. In addition, NO mediates direct
effects by S-nitrosylation of NF-κB p50 and p65 and reduces its
DNA-binding activity [52,53].
3.2. NO-mediated inhibition of Snail
Snail is a member of the Snail superfamily of zinc ﬁnger tran-
scription factors. It plays important roles in embryonic develop-
ment, neural differentiation, cell division, survival, invasion, EMT
and metastasis [54,55]. Snail transcription is regulated, in part, by
both NF-κB [56] and YY1 [57]. Snail represses the transcription of
the metastasis suppressor E-cadherin [58] and RKIP [59].Treatment of tumor cells with the NO donor, DETA-NONOate, in-
hibited Snail expression via NO-mediated inhibition of NF-κB and
its target genes Snail and YY1[37,47]. Also, inhibition of Snail re-
sulted in the derepression of E-cadherin and the induction of RKIP.
3.3. NO-mediated inhibition of YY1
The transcription factor YY1 is a DNA-binding factor that is
multifunctional; it activates, represses or initiates transcription
through either direct binding to DNA or indirectly through com-
plexing with other DNA-binding proteins [60]. Our earlier ﬁndings
demonstrated that YY1 represses the transcription of both Fas and
DR5 and, hence, its role in immune resistance [61,62]. We have
also reported that the treatment of tumor cells with the NO donor,
DETA-NONOate, resulted in the S-nitrosylation of YY1 and further
inhibition of its DNA-binding activity [63].
3.4. NO-mediated induction of RKIP
The Raf kinase inhibitory protein (RKIP) is a member of the
phosphatidylethanolamine-binding protein family (PEBP) and it
has been reported to play a role in lipid metabolism and phos-
pholipid membrane biogenesis [64]. Yeung and colleagues were
the ﬁrst to clone RKIP and demonstrate its inhibitory effects on
both the Raf/MEK/ERK and NF-κB pathways [65,66]. It has also
been reported that RKIP negatively regulates the activation of
G-protein coupled receptors (GPCRs) [67]. The metastatic inhibitor
RKIP is signiﬁcantly depressed in many tumors and almost absent
in metastatic tumors [68–72].
Treatment of tumor cells with the NO donor, DETA-NONOate,
resulted in signiﬁcant upregulation of RKIP expression. This up-
regulation was the result of NO-mediated inhibition of NF-κB and
its target the RKIP repressor Snail. The upregulation of RKIP sub-
sequently results in the inhibition of both the NF-κB and the
MAPK pathways and, thus, amplifying the inhibition of NF-κB,
Snail and YY1 and upregulation of PTEN and RKIP.
3.5. NO-mediated induction of PTEN
PTEN is involved in the inhibition of the PI3K/AKT pathway
[73]. It has been reported that both Snail and YY1 negatively
regulate PTEN expression. In tumor cells whereby the NF-κB, Snail
and YY1 are activated, they result in in the inactivation of PTEN
and, thus, promoting the activation of the survival and anti-
apoptotic PI3K/AKT pathway. The inhibition of NF-κB, Snail and
YY1 by NO results in the derepression of PTEN and its upregulation
and, thus, resulting in PTEN-mediated inhibition of the PI3K/AKT
pathway and downstream target genes involved in both pro-
liferation and anti-apoptosis [38].4. NO-mediated immune-sensitization to apoptosis
Cytotoxic lymphocytes, primarily CTL and NK cells, mediate
their cytotoxic activities by both necrosis and apoptosis. The in-
duction of apoptosis is the result of CTL or NK activation following
recognition and binding to the corresponding receptors on the
target cell. The activation of the cytotoxic cell results in the utili-
zation of the perforin/granzyme mechanism as well as the extra-
cellular activation of the Fas-L, TRAIL and TNF-α- and their inter-
actions and activation of their corresponding receptors [74].
There have been many approaches undertaken to reverse tu-
mor cell resistance to cytotoxic stimuli. Among these are the use of
nonspeciﬁc as well as speciﬁc sensitizing agents that modify the
anti-apoptotic threshold of resistance and, thus, rendering the
modiﬁed cells more susceptible to respond and be killed by the
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treatment of drug/immune resistant tumor cells with NO donors
sensitizes the cells to apoptosis by chemo-immunotherapeutic
agents.
The majority of our studies used the NO donor, DETA-NONOate,
a member of the family of diazoniumdiolate (formerly NONOate).
DETA-NONOate spontaneously dissociates in a pH-dependent ﬁrst
order process and has a half-life of 20 h and 50 h at 37 °C and 22–
25 °C, pH 7.4, respectively. It liberates two moles of NO per mole of
the parent compound DETA-NONOate [76,77].
4.1. NO-mediated sensitization to FasL apoptosis
Our initial original ﬁndings regarding the role of NO-mediated
sensitization of immune resistant cancer cells to apoptosis was the
result of investigating the underlying mechanism by which inter-
feron-γ (IFN-γ) sensitized Fas-resistant tumor cell lines to FasL
apoptosis. We observed that treatment of the tumor cells with
IFN-γ induced the upregulation of Fas expression on the cell sur-
face [78]. It was also known that IFN-γ induces iNOS and NO re-
lease and, thus, we hypothesized that NO may be involved in the
sensitization to FasL-mediated apoptosis. Hence, when the tumor
cells were treated with an NO donor, SNAP, it resulted in the up-
regulation of Fas and sensitization to FasL-mediated apoptosis,
mimicking IFN-γ treatment. The direct role of NO-mediated sen-
sitization by IFN-γwas corroborated by the use of the NO inhibitor,
L-NAME, which abrogated IFN-γ-mediated sensitization to FasL
[78]. The molecular mechanism of NO-mediated upregulation of
Fas was likely the result of either the activation of a transcription
factor on the Fas promoter or the inhibition of a Fas transcription
repressor. Analysis of the Fas promoter identiﬁed a silencer region
with consensus binding sites for the transcription factor YY1. YY1
has been reported to act as both an activator and as a repressor
[60]. Hence, deletion of the silencer region of the Fas promoter
resulted in a signiﬁcant augmentation of the Fas reporter activity.
Also, treatment of tumor cells with DETA-NONOate resulted in the
inhibition of YY1-DNA binding activity as assessed by EMSA [61].
In addition, DETA-NONOate treatment of the tumor cells resulted
in the S-nitrosylation of YY1 and inhibition of its DNA-binding
activity [41]. Overall, the ﬁndings revealed that treatment of tumor
cells with DETA-NONOate resulted in the signiﬁcant release of NO
and consequent inhibition of the Fas YY1 repressor, the induction
of Fas and sensitization to FasL-mediated apoptosis. The sensiti-
zation was the result of activation of the apoptotic pathway trig-
gered by Fas and by NO and involved both type I and type II
apoptotic pathways.
4.2. NO-mediated sensitization to TNF-alpha apoptosis
Several lines of evidence supported the role of the con-
stitutively activated NF- κB pathway in cancer cells as pivotal of
tumor cells resistance to TNF-α apoptosis [79,80]. TNF-α interacts
with two distinct cell surface receptors, TNF-R1 and TNF-R2, and
most cytotoxic effects of TNF-α are mediated by interaction with
TNF-R2 [81]. TNF-α triggers the induction of various reactive
oxygen species (ROS) [82], hence, the use of antioxidants inhibited
TNF-α-mediated effects [83].
The ROS generated by TNF-α results from enzymatic partial
reduction of oxygen yielding superoxide anion (O2 ), which is
immediately reduced by superoxide dismutase to H2O2 or reacts
with NO to generate ONOO [84].
Treatment of tumor cells with IFN-γ sensitized the cells to TNF-
α apoptosis and induction of iNOS. Treatment of tumor cells with
the NOS inhibitor, L-NMA, inhibited IFN-γ-mediated sensitization
to TNF-α. In contrast, treatment with an NO donor (e.g., S-nitroso-
N-acetylpencillamine) sensitized tumor cells to TNF-α apoptosis[51]. This ﬁnding shows that NO interferes with TNF-α-induced
NF-κB activity by reacting with O2 and reducing the TNF-α H2O2-
mediated activation of NF-κB.
4.3. NO-mediated sensitization to TRAIL apoptosis
Reported studies using chemotherapeutic drugs and NF-κB
inhibitors showed that their use with TRAIL-resistant cancer cells
resulted in their sensitization to TRAIL apoptosis concurrently with
upregulation of DR-4 or DR-5 expression [34,85–87]. The ﬁnding
that NO inhibits NF-κB led us to hypothesize that NO can also
sensitize TRAIL-resistant tumor cells to apoptosis by TRAIL.
Treatment of tumor cells with DETA-NONOate sensitized the tu-
mor cells to TRAIL apoptosis concomitantly with upregulation of
DR-5 [34]. Similar to our ﬁndings with Fas-induced upregulation
by NO, there were YY1 consensus binding sites on the DR-5 pro-
moter. Treatment with DETA-NONOate augmented DR-5 reporter
activity and transcription of cells with DR-5 constructs lacking YY1
binding sites or mutation of the YY1 sites, all of which resulted in
enhancement of reporter activity. The direct role of YY1 on the
suppression of DR-5 transcript was corroborated by the use of
siRNA for YY1. The sensitization by DETA-NONOate of TRAIL-in-
duced apoptosis was mediated by the activation of type-I and
type-II apoptotic pathways. The combination treatment activated
both caspases 9 and 3 and PARP cleavage [34].
Overall, the above ﬁndings demonstrated that NO modulates
the dysregulated NF-κB/Snail/YY1/RKIP loop and results in the
inhibition of NF-κB, Snail and YY1 and the induction of RKIP. These
ﬁndings suggested that each of the gene products in the loop
contributes to the resistance and that each gene product alone is
directly involved in the sensitization of tumor cells to im-
munotherapeutic agents.5. NO-mediated chemosensitization to apoptosis
Several mechanisms have been postulated regarding drug-re-
sistance of tumor cells. Drug-resistance is also a consequence of
the anti-apoptotic machinery in cancer cells since many che-
motherapeutic drugs mediate their cytotoxic activity via apoptosis.
Inhibitors of survival pathways have been reported to reverse drug
resistance. For instance, inhibitors of the constitutively activated
NF-κB pathway have reversed Cis-Diammine-Dichloro-Platinum
(CDDP)-resistant cancer cell lines to respond to CDDP treatments
[88]. The ﬁnding that NO treatment inhibits NF-κB activity led us
to postulate it will also sensitize tumor cells to apoptosis by che-
motherapeutic drugs. Indeed, treatment of human prostate cancer
cell lines with DETA-NONOate and CDDP resulted in signiﬁcant
synergistic apoptosis. Treatment with DETA-NONOate inhibited
anti-apoptotic gene products, particularly, Bclxl and XIAP in these
lines. The combination treatment activated the type-II apoptotic
mitochondrial pathway [89]. Similar ﬁndings have also been re-
ported with CDDP-resistant metastatic colon cancer cell lines [90].
These ﬁndings corroborated an earlier and a ﬁrst report by Wink's
Group, whereby, and under conditions of high concentrations of
NO, tumor cells were sensitized to various chemotherapeutic
drugs [91].
The NO-mediated chemosensitization in prostate cancer cell
lines revealed that both YY1 and Bclxl were inhibited and played
pivotal roles in chemosensitization. Treatment of tumor cells
with either siRNA YY1 or siRNA Bclxl sensitized tumor cells to
CDDP apoptosis. The in vitro ﬁndings of the synergistic apoptotic
activity by the combination treatment were corroborated in vivo
in mice bearing PC3 tumor xenografts. Treatment with the
combination of CDDP and DETA-NONOate in vivo, but not a
single agent alone, resulted in synergistic inhibition of tumor
B. Bonavida, H. Garban / Redox Biology 6 (2015) 486–494490growth [89].6. NO-mediated interference in the NF-κB/Snail/YY1/RKIP loop
and the role of each gene product in chemo-
immunosensitization
6.1. Role of NO-mediated inhibition of NF-kB in chemo-
immunosensitization
The NF-κB activity is inhibited by NO and resulting in the in-
hibition of the anti-apoptotic target genes as well as the dere-
pression of pro-apoptotic gene products [34,92,93]. Various NO
donors have been reported which inhibited NF-κB activity and
sensitized drug-resistant tumor cells to cytotoxicity [94,95]. The
implication of NF-κB -induced inhibition by NO in chemo-im-
munosensitization was corroborated by the use of NF-κB in-
hibitors, for example DHMEQ, which mimicked NO in both chemo
and immunosensitizations of tumor cells to CDDP and TRAIL
apoptosis, respectively [34,96].
6.2. Role of NO-mediated inhibition of YY1 in chemo-
immunosensitization
The transcription factor YY1 is under the transcriptional control
of NF-κB [42]. Hence, inhibition of NF-κB will also result in the
inhibition of YY1. In addition, NO directly nitrosylates YY1 and
inhibits its DNA-binding activity [63]. The direct role of YY1 in
chemo-sensitization was corroborated by the use of siRNA YY1.
Treatment of tumor cells with siRNA YY1 sensitized tumor cells to
CDDP apoptosis [89].
6.3. Role of NO-mediated inhibition of Snail in chemo-
immunosensitization
The transcription regulation of the zinc transcription factor
Snail is under the control of both NF-κB [56] and YY1 [57]. It has
also been reported that Snail represses E-cadherin [58] and RKIP
[59].
Treatment of tumor cells with the NO donor DETA-NONOate
inhibited Snail mRNA and protein expressions. In addition, Snail
was S-nitrosylated that inhibited its DNA-binding activity. Further,
Snail was also involved in the reversal of chemo-immune re-
sistance. The direct role of Snail was demonstrated by treating the
resistant cells with Snail siRNA and the tumor cells were sensitized
to apoptosis by both chemotherapeutics and immunotherapeutics
[37,97]. Treatment with Snail siRNA resulted in modiﬁcation of the
regulatory loop by inhibiting NF-κB, YY1 and Snail and the in-
duction of RKIP.
6.4. Role of RKIP-mediated upregulation by NO in chemo-
immunosensitization
The ﬁrst demonstration that RKIP plays a role in the regulation
of drug resistance was reported by Chatterjee et al. [98], whereby
they reported that the overexpression of RKIP in prostate cancer
cell lines sensitized the cells to apoptosis by Camptothecin (CPT-1).
Also, we have reported that overexpression of RKIP sensitizes cells
to TRAIL apoptosis [45].
Since treatment of tumor cells with DETA-NONOate resulted in
the upregulation of RKIP, we postulated that the induction of RKIP
concomitantly with inhibition of the resistant factors NF-κB, Snail
and YY1 will be involved in chemo-immunosensitization of re-
sistant tumor cells. Treatment of tumor cells with DETA-NONOate
resulted in the upregulation of RKIP mRNA and protein expres-
sions in tumor cell lines and the cells were sensitized to apoptosisby cytotoxic drugs. The direct role of RKIP in chemo-immuno-
sensitization was corroborated by the use of cells treated with
siRNA RKIP, which resulted in the reversal of tumor cell sensitivity
to TRAIL apoptosis [45].
Clearly, all of the above ﬁndings point out that each gene
product of the loop plays a direct role in chemo-im-
munosensitization to apoptosis by both chemo and im-
munotherapeutic drugs. However, the direct role of Snail, YY1 and
RKIP in chemo-immunosensitization is not totally clear since they
are all interregulated. To approach the direct roles, one has to in-
vestigate tumor cells that are, for example, inhibited for NF-κB
activity and then were transduced to overexpress Snail, YY1 or
RKIP and examine their sensitization to drugs.7. Comparison between NO donors and other chemo-im-
munosensitizing agents
There have been many reports of using various agents that
reverse tumor cell resistance and sensitized the cells to apoptosis
by chemo-immunotherapeutics [99]. Various agents have targeted
the NF-κB, Snail, YY1, RKIP loop and the results showed similar
ﬁndings to those mediated by treatment with NO donors. For ex-
ample, we have reported that treatment of tumor cells with sub-
toxic concentrations of chemotherapeutic drugs sensitized the
cells to both FasL and TRAIL apoptosis [100–102]. These ﬁndings
were subsequently corroborated by treatment with NO donors
[103]. Also, treatment with subtoxic concentrations of drugs sen-
sitized the tumor cells to TRAIL apoptosis [104].
Treatment with chemotherapeutic drugs resulted in the upre-
gulation of DR4 or DR5, concomitantly with sensitization to TRAIL
apoptosis [105,106]. However, the molecular underlying mechan-
isms were not known. In our prior ﬁndings [96] we reported that
treatment with an NO donor upregulated DR5 concomitantly with
sensitization to TRAIL apoptosis. The mechanism of DR5 upregu-
lation was the result of NO-mediated inhibition of the DR5 re-
pressor YY1. We have also reported that treatment of B-NHL tumor
cells with rituximab sensitized the cells to both chemo and im-
munotherapeutics. Sensitization was the result of inhibition of the
NF-κB, Raf-1, and PI3K pathways [36,107–109]. These ﬁndings
were reproduced with NO donors and showed that rituximab and
the NO donor behaved similarly. Inhibitors for NF-κB also mi-
micked NO donors in tumor cell sensitization. Hence, treatment of
tumor cells with NF-κB inhibitors sensitized the tumor cells to
apoptosis by cytotoxic drugs. One example is the use of the NF-κB
inhibitor, DHMEQ, which resulted in sensitization to FasL and
TRAIL and chemotherapeutic drugs [44]. Likewise, we have shown
that the NO donor, which inhibited NF-κB, also resulted in the
reversal of resistance and, thus, mimicking the NF-κB inhibitor. In
addition, treatment with proteasome inhibitors resulted in tumor
cell sensitization mimicking NO donors. For example, treatment
with bortezomib was shown to sensitize tumor cells to TRAIL
apoptosis. Bortezomib inhibits NF-κB activity like NO donors [45].
Like NO donors, treatment with another proteasome inhibitor,
NPI0052, resulted in the inhibition of NF-κB, Snail, and YY1 and
induction of RKIP.
The above ﬁndings demonstrated that treatment with NO do-
nors mimicked many sensitizing agents, some of which are clini-
cally used (Bortezomib) and suggest the use of NO donors in vivo
in patients in combination with subtoxic cytotoxic therapies. Fur-
ther, it is not clear whether the development of tumor sensitizing
agents can be also applied for novel sensitizing NO donors.
Fig. 1. NO donors convert the anti-apoptotic NF-κB/Snail/YY1/RKIP/PTEN resistant
loop into a sensitive pro-apoptotic loop. The schematic diagram represents tumor
cells that have a dysregulated NF-κB/Snail/ YY1/RKIP/PTEN resistant loop involved
in the maintenance of the tumor cell viability, proliferation, resistance, EMT, and
metastasis. Hence, in tumor cells, the expression and the activities of NF-κB, Snail,
YY1 are upregulated while those of RKIP and PTEN are downregulated. The loop is
the result of NF-κB-mediated activation of its target Snail and YY1 and, in turn,
Snail represses RKIP and YY1 represses PTEN. In addition, YY1 activates Snail. In the
presence of NO donors, the activities of NF-κB, Snail and YY1 are inhibited and
resulting in the de-repression of RKIP and PTEN. In turn, RKIP potentiates its in-
hibitory activity on NF-κB and its targets and, likewise, PTEN inhibits the PI3K/Akt
pathway which controls NF-κB. Overall, the NO treatment inhibits tumor cell via-
bility, proliferation and sensitizes the cells to chemo-immunotherapies-induced
apoptosis.
Fig. 2. Mechanism of NO-mediated chemo-immunosensitization of resistant tumor
cells to apoptosis. The schematic diagram represents the NO-mediated effects that
results in the sensitization of resistant tumor cells to drug-immune-induced
apoptosis. Both NO donors and iNOS induction will result in the upregulation of NO,
resulting in the upregulation of death receptors and sensitization to death ligands
(FasL, TRAIL, TNF-α) and activation of the effector caspase 3 and downstream
apoptosis. Also, NO will inhibit anti-apoptotic gene products such as Bcl-2 and
allowing cytotoxic drugs to act on the mitochondrial membrane and resulting on
the activation of caspase 3 or induction of AIF, all of which result in apoptosis.
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8.1. Preclinical
An NO donor synthesized by Keefer's Lab at NIH, JS-K, is a
diazonium diolate and releases NO enzymatically activated by
glutathione and glutathione-S-transferase (GST) [110]. Findings by
Weyerbroch et al. [111] reported the inhibition of proliferation and
induction of apoptosis in vivo of U87 glioma tumors xenografts
treated with JS-K. In a colo-rectal carcinoma model, Huerta et al.[112] used mice bearing the human metastatic CRC line, SW620,
and treated the mice with DETA-NONOate and chemotherapy. This
combination treatment resulted in inhibition of tumor cell growth.
Pervin et al. [113] reported the treatment of tumor-bearing mice
with the combination of DETA-NONOate and a farnesyl transferase
inhibitor showed minimal toxicity and slowed the growth of the
tumor. Also, the combination of DETA-NONOate and CDDP en-
hanced the cytotoxic activity of S29 lung ﬁbroblasts [91], and si-
milar results were achieved with head and neck cancers [114].
Huerta-Yepez et al. [89] reported tumor inhibition by treatment
with the combination of DETA-NONOate and CDDP in mice bear-
ing human prostate cancer xenografts.
In addition to NO donors, reports utilized gene therapy via
inducible NOSII for cancer therapy [115]. Another NO donor, JS-K,
was studied in castrated-resistant prostate cancer cells and re-
sulted in the attenuation of functional androgen receptor signaling
with inhibition of cell growth [116]. Also, NO-NSAID donors were
examined in a variety of tumor cell lines and exhibited inhibition
of cell proliferation and induction of apoptosis [117–119].
The anticancer effect of iNOS was ﬁrst reported by Xie et al.
[120]. The in vivo model used mice bearing tumors overexpressing
iNOS and resulted in inhibition of tumor growth and additional
studies were also reported by Xie and Fiddler [121]. Chung et al.
[122] reported signiﬁcant apoptosis in cells transfected with the
iNOS gene and other studies have been reviewed elsewhere
[33,115].
The antitumoral properties of NOS-3 overexpression by gene
therapy was reported [123,124].
8.2. Clinical
Several reports have delineated the important role of NO in
cancer therapy. It may act directly as a cytotoxic agent against
cancer cells or sensitizes resistant tumor cells to chemo-immuno-
radio-hormonal therapies [125,126].
The initial application of the NO donor, nitroglycerine (GTN), in
patients was reported by Yasuda et al. [127,128] whereby they
treated patients with lung cancer with the combination of GTN
and vinorelbine and CDDP and showed an improved response of
72% and median time to progression compared to patients without
GTN. Siemens et al. [129] reported a phase II study using patches
releasing GTN in prostate cancer patients who failed primary
treatment. This treatment reduced hypoxia-induced progression
as measured by a decrease in the PSA doubling time. Siemens et al.
[130] used a GTN patch that slowly releases GTN in combination
with anti-cancer treatment with drugs that resulted in signiﬁcant
inhibition of PSA in patients with prostate cancer. Arrieta et al. [32]
reported the ﬁrst clinical study that the addition of GTN to in-
duction chemotherapy and concurrent chemo-immunotherapy in
patients with local advanced NSCCL resulted in acceptable toxicity
proﬁle.9. Concluding remarks and future directions
It is clear that high levels of NO, either biologically generated by
iNOS or by NO donors, exert several anti-tumor activities, namely,
inhibition of cell survival and growth, sensitizing the tumor cells
to both chemo, immune- and radio-toxicities, and also inhibit EMT
and metastasis. The mechanisms mediating these various NO-
mediated effects are, in part, under the regulation of the con-
stitutively activated and dysregulated pro-survival/anti-apoptotic
of the NF-κB/Snail/RKIP/PTEN loop in cancer cells. NO interferes
directly in the loop by inhibiting the activities NF-κB, Snail and
YY1 and derepressing the expressions of the anti-survival/pro-
apoptotic gene products RKIP and PTEN (see schematic diagrams
B. Bonavida, H. Garban / Redox Biology 6 (2015) 486–494492Figs. 1 and 2). These NO-mediated manifestations, both in vitro
and in vivo in mouse models, support the potential therapeutic
application of NO donors in combination with subtoxic therapeutic
agents on the reversal of tumor resistance and the inhibition of
both EMT and metastasis. Phase I/II clinical studies are under
current investigation to support the contention of the anti-tumor-
mediated effects of NO [see reviews in this volume]. Clearly, phase
III clinical trials will be hopefully investigated in the future and we
are eagerly awaiting the ﬁndings for the novel therapeutic appli-
cation of NO in cancer. It must be noted also that while NO donors
are not highly tumor speciﬁc, their pleiotropic activity in the re-
versal of resistance and sensitizing activity are paralleled with
inhibition of EMT and metastasis. Various laboratories are devel-
oping novel NO donors with better efﬁcacies as single agents or
complexed with other targeting agents for speciﬁcity.Acknowledgements
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